The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $52.66 in the last session, up 1.60% from day before closing price of $51.83. In other words, the price has increased by $1.60 from its previous closing price. On the day, 1.49 million shares were traded. CRSP stock price reached its highest trading level at $53.4 during the session, while it also had its lowest trading level at $50.83.
Ratios:
We take a closer look at CRSP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 16.61 and its Current Ratio is at 16.61. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35. On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Kulkarni Samarth sold 13,081 shares for $58.15 per share. The transaction valued at 760,660 led to the insider holds 207,004 shares of the business.
Treco Douglas A bought 20,000 shares of CRSP for $1,140,600 on Aug 06 ’25. The Director now owns 22,000 shares after completing the transaction at $57.03 per share. On Jul 16 ’25, another insider, George Simeon, who serves as the Director of the company, bought 989,812 shares for $52.03 each. As a result, the insider paid 51,499,918 and bolstered with 1,730,179 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 4789448192 and an Enterprise Value of 3283664384. For the stock, the TTM Price-to-Sale (P/S) ratio is 125.87 while its Price-to-Book (P/B) ratio in mrq is 2.72. Its current Enterprise Value per Revenue stands at 86.299 whereas that against EBITDA is -7.51.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.81, which has changed by 0.16944253 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $71.13, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is -5.53%, while the 200-Day Moving Average is calculated to be 16.69%.
Shares Statistics:
According to the various share statistics, CRSP traded on average about 3.24M shares per day over the past 3-months and 1678620 shares per day over the past 10 days. A total of 88.38M shares are outstanding, with a floating share count of 86.10M. Insiders hold about 5.33% of the company’s shares, while institutions hold 77.09% stake in the company. Shares short for CRSP as of 1755216000 were 23309013 with a Short Ratio of 7.19, compared to 1752537600 on 25295875. Therefore, it implies a Short% of Shares Outstanding of 23309013 and a Short% of Float of 28.939999999999998.
Earnings Estimates
The dynamic stock of CRISPR Therapeutics AG (CRSP) is currently being evaluated by a team of 13.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$1.09, with high estimates of $0.16 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.16 and -$7.33 for the fiscal current year, implying an average EPS of -$6.12. EPS for the following year is -$4.64, with 17.0 analysts recommending between -$2.25 and -$6.71.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $128.26M, while the lowest revenue estimate was $1.76M, resulting in an average revenue estimate of $35.45M. In the same quarter a year ago, actual revenue was $37.31M
